Non-Proliferative Diabetic Retinopathy Market Report 2026

Non-Proliferative Diabetic Retinopathy Market Overview

• Non-Proliferative Diabetic Retinopathy market size has reached to $2.83 billion in 2025 • Expected to grow to $3.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Surging Prevalence Of Diabetes Fuels Growth In The Non-Proliferative Diabetic Retinopathy Market • Market Trend: AXPAXLI Phase 3 Registrational Trial Initiation Strengthens Non-Proliferative Diabetic Retinopathy Treatment Pipeline • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Proliferative Diabetic Retinopathy Market?

Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision. The main types of treatment for non-proliferative diabetic retinopathy include anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injection, laser surgery, and vitrectomy. Anti-vascular endothelial growth factor (VEGF) therapy involves the use of medications that inhibit vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth in the retina. This treatment is given for different severity levels include mild non-proliferative diabetic retinopathy, moderate non-proliferative diabetic retinopathy, and severe non-proliferative diabetic retinopathy in hospitals, specialty clinics, ambulatory surgical centers, and others.

What Is The Non-Proliferative Diabetic Retinopathy Market Growth Forecast?

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising prevalence of diabetic retinopathy, increasing adoption of anti-vegf and steroid therapies, expansion of ophthalmology clinics and specialty centers, growth in advanced retinal imaging technologies, improving patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of anti-vegf therapy in npdr, increasing use of intraocular steroid injections, growing implementation of advanced laser surgery techniques, expanding deployment of vitrectomy procedures, advancing integration of ai-powered retinal imaging and diagnosis.

What Is The Driver Of The Non-Proliferative Diabetic Retinopathy Market?

The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body's cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy industry.

Key Players In The Global Non-Proliferative Diabetic Retinopathy Market

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.

Global Non-Proliferative Diabetic Retinopathy Market Trends and Insights

Major companies operating in the non-proliferative diabetic retinopathy (NPDR) market are focusing on developing advanced clinical solutions, such as Phase 3 registrational trial enrollment, to enhance therapeutic validation, generate robust evidence, and support regulatory approval for emerging NPDR treatments. Phase 3 registrational trial enrollment refers to the formal initiation and randomization of patients into a pivotal late-stage clinical trial designed to produce comprehensive efficacy and safety data needed for market authorization of a therapeutic intervention. For instance, in November 2025, Ocular Therapeutix, a US-based biopharmaceutical company specializing in retinal diseases, announced the first patient randomization in the HELIOS-3 Phase 3 registrational program evaluating AXPAXLI (OTX-TKI) for NPDR. AXPAXLI is an investigational bioresorbable intravitreal hydrogel containing axitinib, a tyrosine kinase inhibitor with anti-angiogenic activity, engineered to deliver sustained therapy with fewer injections. The HELIOS-3 trial, along with HELIOS-2, utilizes a novel ordinal ≥2-step Diabetic Retinopathy Severity Score (DRSS) improvement as the primary endpoint and includes patients with non-center-involved diabetic macular edema (non-CI-DME), positioning AXPAXLI as a potentially transformative option for durable and effective NPDR management.

What Are Latest Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy Market?

In March 2024, Sandoz, a Switzerland-based provider of generic and biosimilar medicines, acquired the ophthalmology subsidiary of Coherus BioSciences Inc., including the CIMERLI (ranibizumab-eqrn) business, for $170 million. Through this acquisition, Sandoz aims to reinforce its position in the U.S. ophthalmology and biosimilar markets by expanding its portfolio of treatments for retinal diseases such as non-proliferative diabetic retinopathy. Coherus BioSciences Inc. is a US-based biopharmaceutical company that previously commercialized the CIMERLI biosimilar for retinal disorders.

What Defines the Non-Proliferative Diabetic Retinopathy Market?

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Proliferative Diabetic Retinopathy Market Report 2026?

The non-proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.